Crisaborole vesus tacrolimus ointment in the treatment of atopic dermatitis
Phase 3
- Conditions
- Health Condition 1: - Health Condition 2: L209- Atopic dermatitis, unspecified
- Registration Number
- CTRI/2024/05/067660
- Lead Sponsor
- Dr Disha Chakraborty
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients to be aged 2 years or older of either sex
They must have a clinical diagnosis of AD according to Hanifin and Rajka criteria
They should have 5% or more treatable body surface area involvement, and a baseline Investigator’s Static Global Assessment (ISGA) score of mild (2) or moderate (3).
Exclusion Criteria
active infections or use of topical steroids in last 14 days
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the efficacy of 2% crisaborole ointment for treating mild to moderate cases of AD to achieve a clear or near clear skin (ISGA score 0 or 1) at baseline and in 4 weeks.Timepoint: At baseline and in 4 weeks
- Secondary Outcome Measures
Name Time Method To determine the change in pruritus score with both the treatment groups and compare between themTimepoint: 4 weeks